1.
ClinicalTrials.gov; 11/02/2024; TrialID: NCT06255600
Clinical Trial Register
| ICTRP | ID: ictrp-NCT06255600
ABSTRACT
Condition:
Cardiovascular Diseases;Long Covid19Intervention:
Other: High Definition-transcranial Direct Current Stimulation;Dietary Supplement: Chlorella PyrenoidosaPrimary outcome:
Increasead B12 by blood analysis biochemicalCriteria:
Inclusion Criteria:
- Patients with cardiovascular diagnosis or risk;
- Adults and elderly people (18 to 80 years old);
- Able to respond to commands and grant consent to participate in the research through
the informed consent form;
- Who have post-COVID symptoms.
Exclusion Criteria:
- Patients with a clinical history of neuromuscular or cognitive instability, pregnancy
and contraindications for receiving neurostimulation (such as cardiac pacemakers and
metallic brain implants);
- Patients with contraindications to the use of Chlorella (gastritis, esophagitis,
peptic ulcers),
- Pregnant patients, patients with stroke and tumors
2.
ClinicalTrials.gov; 16/03/2022; TrialID: NCT05289115
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05289115
ABSTRACT
Condition:
Coronavirus;COVID-19 Respiratory InfectionIntervention:
Device: Experimental group/ Active HD-tDCS;Device: Control Group / Sham GroupPrimary outcome:
Fatigue ImpactCriteria:
Patients who had a medical diagnosis of COVID-19, clinically stable, able to respond to
simple commands, able to walk for six minutes and who sign study consent form will be
enrolled. Those who present associated neurological diseases, pregnant, users of
psychoactive drugs, patients who have metallic implants, electronic devices, pacemakers, or
epileptic patients will be excluded.
3.
ClinicalTrials.gov; 16/03/2022; TrialID: NCT05289128
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05289128
ABSTRACT
Condition:
Coronavirus COVID-19;Respiratory InfectionIntervention:
Device: Experimental group;Device: Sham ControlPrimary outcome:
Responders and non-responders to treatment with HD-tDCSCriteria:
Patients who had a medical diagnosis of COVID-19, clinically stable, able to respond to
simple commands, able to walk for six minutes and who sign study consent form will be
enrolled. Those who present associated neurological diseases, pregnant, users of
psychoactive drugs, patients who have metallic implants, electronic devices, pacemakers, or
epileptic patients will be excluded.
4.
ClinicalTrials.gov; 29/03/2021; TrialID: NCT04844554
Clinical Trial Register
| ICTRP | ID: ictrp-NCT04844554
ABSTRACT
Condition:
Coronavirus;COVID-19 Respiratory InfectionIntervention:
Other: Active HD-tDCS 3mA;Other: Sham HD-tDCSPrimary outcome:
ICU's primary outcome - Duration of mechanical ventilationCriteria:
Intensive Care Unit's Inclusion Criteria:
- All patients diagnosed with COVID-19, mechanically ventilated for at least 24 hours,
admitted to the Intensive Care Unit for treatment will be selected for eligibility.
- Those patients who are not sedated or have an adequate level of awakening (Richmond
Agitation Score- Sedation Scale (RASS) > -3 at the time of inclusion in the study
within 48 hours after stopping sedation and are able to respond to simple commands
will be eligible) and to provide your informed consent.
Intensive Care Unit's Exclusion Criteria:
- Exclusion criteria will be: coma (GCS= 8); intense agitation, clinical history of
neuromuscular or cognitive instability, pregnancy and contraindications for
non-invasive cerebral stimulation.